Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. received a contract valued up to $18.2 million from the U.S. Department of Defense to develop and manufacture monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19. The goal of this program is to rapidly and efficiently deliver the mAbs to the DOD. Just – Evotec Biologics will design a highly efficient manufacturing process for the production of cGMP clinical supplies of two monoclonal antibodies ...